Skip to main content
. 2015 Mar 19;2015:254169. doi: 10.1155/2015/254169

Figure 2.

Figure 2

Comparison of metabolic/hepatic markers in the three PCOS groups (PCOS-C: patients who were insulin sensitive at baseline; PCOS-PIR: patients with IR at baseline and after treatment; PCOS-exIR: initially insulin resistant patients whose IR dissolved after treatment). Data are presented as percent changes (between baseline and after treatment) of prevalence and were analyzed using Chi²-tests.